Showing results (631-640 of 782) with videos related to
Sort By:
Pageof 79
Cancer Research|September 4, 2012
GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivoMarc S Raab, Iris Breitkreutz, Simon Anderhub, et al.Cancer Cell|April 18, 2006
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patientsDaniel R Carrasco, Giovanni Tonon, Yongsheng Huang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2010
Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemiaIrene M Ghobrial, Aldo Roccaro, Fangxin Hong, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2017
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-AnalysisPhilip L McCarthy, Sarah A Holstein, Maria Teresa Petrucci, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemiaIrene M Ghobrial, Morie Gertz, Betsy Laplant, et al.Blood|January 21, 2012
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myelomaLoredana Santo, Teru Hideshima, Andrew L Kung, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2019
A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple MyelomaIrene M Ghobrial, Chia-Jen Liu, Robert A Redd, et al.Nature Communications|June 15, 2022
Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomesMark Bustoros, Shankara Anand, Romanos Sklavenitis-Pistofidis, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 7, 2006
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomibPaul G Richardson, Hannah Briemberg, Sundar Jagannath, et al.Blood Advances|June 11, 2024
Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapiesShuhui Deng, Sanika Derebail, Vera Joy Weiler, et al.Pageof 79